Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia
β Scribed by Richard E. Clark
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 138 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a consequence of the formation of the __bcrβabl__ oncogene. The particular molecular basis of this condition has enabled the development of therapies that selectively target diseased cells. The
Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per
6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for
Thirty-seven patients with chronic phase chronic myeloid leukaemia and fourteen healthy controls have been evaluated for lineage differentiation with immunological markers on purified bone marrow CD34 positive cells by multiparameter flow cytometry. The myeloidassociated antigen CD33 and the stem ce